Abstract
New compounds having affinity to various melanocortin receptors have recently been identified as possible neuroprotective agents. This review is focused on the role of neuroprotective effects of melanocortins in CNS injury and repair mechanisms. Using selective non-peptidic compounds with varying affinity to melanocortin receptors, our laboratory has shown their anti-edematous effects in the spinal cord injury. This effect of the compounds is related with their ability to attenuate blood-spinal cord barrier permeability. The functional significance and possible therapeutic strategies of these compounds in CNS injury are discussed.
Keywords: Melanocortins, spinal cord injury, edema formation, cell injury, melanocortins receptor, blood-spinal cord barrier
Current Pharmaceutical Design
Title: Neuroprotective Effects of Melanocortins in CNS Injury
Volume: 13 Issue: 19
Author(s): H. S. Sharma, T. Lundstedt, M. Flardh, A. Skottner and L. Wiklund
Affiliation:
Keywords: Melanocortins, spinal cord injury, edema formation, cell injury, melanocortins receptor, blood-spinal cord barrier
Abstract: New compounds having affinity to various melanocortin receptors have recently been identified as possible neuroprotective agents. This review is focused on the role of neuroprotective effects of melanocortins in CNS injury and repair mechanisms. Using selective non-peptidic compounds with varying affinity to melanocortin receptors, our laboratory has shown their anti-edematous effects in the spinal cord injury. This effect of the compounds is related with their ability to attenuate blood-spinal cord barrier permeability. The functional significance and possible therapeutic strategies of these compounds in CNS injury are discussed.
Export Options
About this article
Cite this article as:
H. S. Sharma , T. Lundstedt , M. Flardh , A. Skottner and L. Wiklund , Neuroprotective Effects of Melanocortins in CNS Injury, Current Pharmaceutical Design 2007; 13 (19) . https://dx.doi.org/10.2174/138161207781039797
DOI https://dx.doi.org/10.2174/138161207781039797 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Neurotrophin Receptor Signaling as a Therapeutic Target for Huntington's Disease
CNS & Neurological Disorders - Drug Targets Tetracyclines and Pulmonary Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Recent Patents on CNS Drug Discovery (Discontinued) Guiding Lineage Specific Differentiation of SHED for Target Tissue/Organ Regeneration
Current Stem Cell Research & Therapy Secondary Brain Injuries in Thalamus and Hippocampus after Focal Ischemia Caused by Mild, Transient Extradural Compression of the Somatosensori Cortex in the Rat
Current Neurovascular Research Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Glutamatergic Neurotransmission As Molecular Target of New Anticonvulsants
Current Topics in Medicinal Chemistry Subtype-Selective Noncompetitive Modulators of Metabotropic Glutamate Receptor Subtype 1 (mGluR1)
Current Topics in Medicinal Chemistry Regulatory Triangle of Neurodegeneration, Adult Neurogenesis and MicroRNAs
CNS & Neurological Disorders - Drug Targets Resolvins: Endogenously-Generated Potent Painkilling Substances and their Therapeutic Perspectives
Current Neuropharmacology Non-Analgesic Effects of Opioids: Opioids’ Effects on Sleep (Including Sleep Apnea)
Current Pharmaceutical Design Emerging Therapies for Diabetic Neuropathy: A Clinical Overview
Current Diabetes Reviews Hypoxia-Inducible Factor-1 in Arterial Disease: A Putative Therapeutic Target
Current Vascular Pharmacology Attenuating Effect of Portulaca oleracea Extract on Chronic Constriction Injury Induced Neuropathic Pain in Rats: An Evidence of Anti-oxidative and Anti-inflammatory Effects
CNS & Neurological Disorders - Drug Targets Pulmonary Circulation and Pulmonary Function in Neonatal Lung Hypoplasia:Treatment with Corticosteroids
Current Pediatric Reviews Molecular Pharmacology of the Glycine Receptor Chloride Channel
Current Pharmaceutical Design Pituitary Adenylate Cyclase Activating Polypeptide: A Potential Neuroprotective Peptide
Current Pharmaceutical Design Curcumin Loaded and Co-loaded Nanosystems: A Review from a Biological Activity Enhancement Perspective
Pharmaceutical Nanotechnology Will Medicinal Cannabinoids Prove to be Useful Clinically?
Current Drug Therapy